Literature DB >> 10525123

Evidence for a cholesteryl ester donor activity of LDL particles during alimentary lipemia in normolipidemic subjects.

T S Lassel1, M Guerin, S Auboiron, B Guy-Grand, M J Chapman.   

Abstract

Postprandial hypertriglyceridemia represents an independent risk factor for coronary artery disease. In the postprandial state, elevated levels of triglyceride-rich lipoproteins (TRL) are minor acceptors of HDL-cholesteryl ester (CE) transferred by CETP in normolipidemic subjects: indeed, LDL particles represent the major CE acceptors. In order to evaluate further the potential atherogenicity of lipoprotein particles characteristic of the postprandial phase in normolipidemic subjects, we determined the quantitative and qualitative features of apoB- and apoAI-containing lipoproteins over an 8-h period following consumption of a mixed meal. During postprandial lipemia, we observed a significant decrease (-12%) in plasma AI concentration (138+/-4 and 156+/-4 mg/dl, at 3 h and baseline, respectively, P<0.005). Concomitantly, a progressive increase (+13%) was detected in HDL2 concentrations (138+/-7 mg/dl at 4 h vs. 122+/-12 mg/dl at baseline, P<0.005), as well as a significant reduction (-9%) in HDL3 levels (137+/-6 mg/dl at 3 h vs. 150+/-4 mg/dl at baseline; P<0.05). Additionally, plasma LDL was reduced by 5% (247+/-12 mg/dl at 3 h vs. 260+/-15 mg/dl at baseline; P<0.05) 3 h following meal intake. Moreover, a significant reduction (-10%) occurred in the CE/TG ratio in LDL at 2 h postprandially (8+/-2 at 2 h vs. 9+/-3 at baseline; P<0.005). These changes reflected an increment (17+/-3 mg/dl at 3 h vs. 15+/-4 mg/dl at baseline; P<0.05) in LDL triglyceride concentrations. Despite the high CE acceptor capacity of LDL particles, no measurable increase in their CE content was detected during the postprandial phase. We demonstrated that CE accepted by LDL particles from HDL are secondarily transferred to chylomicrons by CETP. As chylomicrons displayed a 260-fold lower CE/TG ratio than LDL (0.03:1 and 7.8:1 in chylomicrons and LDL, respectively), CE-rich LDL may act to donate CE to chylomicrons. In conclusion, our data indicate that the presence of elevated levels of chylomicrons induces LDL to act as a secondary donor of CE during the postprandial phase.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10525123     DOI: 10.1016/s0021-9150(99)00161-6

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  4 in total

1.  In vitro simultaneous transfer of lipids to HDL in coronary artery disease and in statin treatment.

Authors:  Ana C Lo Prete; Clederson H Dina; Carolina H Azevedo; Camila G Puk; Neuza H M Lopes; Whady A Hueb; Raul Cavalcante Maranhão
Journal:  Lipids       Date:  2009-09-16       Impact factor: 1.880

2.  Effect of dietary cholesterol and fat on cell cholesterol transfer to postprandial plasma in hyperlipidemic men.

Authors:  Wayne H F Sutherland; Sylvia A de Jong; Robert J Walker
Journal:  Lipids       Date:  2007-08-07       Impact factor: 1.646

Review 3.  Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management.

Authors:  M John Chapman; Henry N Ginsberg; Pierre Amarenco; Felicita Andreotti; Jan Borén; Alberico L Catapano; Olivier S Descamps; Edward Fisher; Petri T Kovanen; Jan Albert Kuivenhoven; Philippe Lesnik; Luis Masana; Børge G Nordestgaard; Kausik K Ray; Zeljko Reiner; Marja-Riitta Taskinen; Lale Tokgözoglu; Anne Tybjærg-Hansen; Gerald F Watts
Journal:  Eur Heart J       Date:  2011-04-29       Impact factor: 29.983

4.  Distinct Postprandial Bile Acids Responses to a High-Calorie Diet in Men Volunteers Underscore Metabolically Healthy and Unhealthy Phenotypes.

Authors:  Antonin Lamaziere; Dominique Rainteau; Pukar Kc; Lydie Humbert; Emilie Gauliard; Farid Ichou; Maharajah Ponnaiah; Nadine Bouby; Joe-Elie Salem; Jean-Maurice Mallet; Maryse Guerin; Philippe Lesnik
Journal:  Nutrients       Date:  2020-11-19       Impact factor: 5.717

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.